Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome
Authors:
- 16 August 2019
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 33 (5) , 501-509
Abstract
Purpose Perivascular adipose tissues (PVAT) are involved in the regulation of vascular tone. In mesenteric arteries, the compensatory vasodilatory effects of PVAT appear when vascular relaxation is impaired and disappear at around 23 weeks of age in SHRSP.Z-Leprfa/IzmDmcr (SHRSP.ZF) rats with metabolic syndrome (MetS). The renin-angiotensin system is involved in the development of endothelium and vascular dysfunction. Therefore, we investigated whether azilsartan, a potent angiotensin II type 1 (AT1) receptor antagonist, can protect against the deterioration of the PVAT compensatory vasodilator function that occurs with aging in MetS. Methods Two age groups of SHRSP.ZF rats (13 and 20 weeks of age) were administered azilsartan or vehicle through oral gavage once daily for 10 weeks. The vasodilation response of the isolated superior-mesenteric arteries upon addition of endothelium-dependent and -independent agonists was determined in the presence or absence of PVAT using organ bath methods. Results In vivo treatment with azilsartan improved the acetylcholine-induced vasodilation in mesenteric arteries with and without PVAT at both time-points. The mRNA levels of AT1 receptor and AT1 receptor-associated protein were unchanged in PVAT upon azilsartan treatment. Furthermore, in vitro treatment with azilsartan (0.1 and 0.3 μM for 30 min) did not affect the compensatory effect of PVAT on vasodilation in response to acetylcholine in SHRSP.ZF rat mesenteric arteries. Conclusions Our results provide evidence supporting the use of azilsartan for the long-term protection against vascular dysfunctions in MetS. Azilsartan did not improve the dysfunction of PVAT-mediated modulation of vascular tone during MetS. The protective effect of azilsartan is mediated by restoring the endothelium- and vascular smooth muscle-mediated mechanisms.Keywords
Funding Information
- Japan Society of Physiological Anthropology (JP16K08563)
This publication has 30 references indexed in Scilit:
- Angiotensin Receptor–Binding Protein ATRAP/ Agtrap Inhibits Metabolic Dysfunction With Visceral ObesityJournal of the American Heart Association, 2013
- Azilsartan Medoxomil: A New Angiotensin Receptor BlockerClinical Therapeutics, 2011
- Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky ratsDiabetes, Obesity and Metabolism, 2011
- Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Leprfa/IzmDmcr rats with metabolic syndromeCanadian Journal of Physiology and Pharmacology, 2011
- In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function StudiesThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Coronary vascular dysfunction promoted by oxidative‐nitrative stress in SHRSP.Z‐Leprfa/IzmDmcr rats with metabolic syndromeClinical and Experimental Pharmacology and Physiology, 2010
- Effect of Losartan on Vascular Function in Fructose-Fed Rats: The Role of Perivascular Adipose TissueClinical and Experimental Hypertension, 2010
- Comparative expression analysis of the renin–angiotensin system components between white and brown perivascular adipose tissueJournal of Endocrinology, 2008
- Cardiovascular Remodeling and Metabolic Abnormalities in SHRSP.Z-Leprfa/IzmDmcr Rats as a New Model of Metabolic SyndromeHypertension Research, 2008
- Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) ratsClinical and Experimental Pharmacology and Physiology, 2004